Your session is about to expire
← Back to Search
DCE MRI for Pancreatic Cancer
This trial is looking at using magnetic resonance imaging (MRI) to better identify pancreatic cancer in high risk patients or patients who have undergone chemotherapy.
- Pancreatic Cancer
- Pancreatic Neoplasm
- Pancreatic Adenocarcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2013 Phase 2 trial • 44 Patients • NCT00227760
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have been diagnosed with a condition called hemochromatosis or other conditions related to too much iron in your body.Group 3 participants must have been diagnosed with pancreatic cancer, confirmed by a pathology test, and may or may not have received chemotherapy before surgery.You have multiple allergies to different medications, including intravenous iron replacement products. You have also had a bad reaction to ferumoxytol in the past or are known to be very sensitive to it.You have liver disease, heart problems, or a condition that causes your skin to turn bronze.
- Group 1: Arm III (Pancreatic cancer)
- Group 2: Arm I (High-risk for familial/hereditary pancreatic cancer)
- Group 3: Arm IV (Healthy volunteers)
- Group 4: Arm II (IPMN)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor accept subjects that are 45 years and older?
"According to the eligibility requirements of this trial, any patient aged 18-85 is able to participate."
What are the projected results of this research?
"The primary aim of this medical trial, with an expected duration of up to 5 years, is to determine the presence or lack thereof of pancreatic cancer in patients suffering from cystic lesions. Secondary objectives include evaluating disease-free survival through Kaplan-Meier analysis and overall survival along with surgical diagnostic measures using AJCC TNM staging system as potential confounders or modifiers for the model. The c-statistics will be reported on each model."
Are there any prior experiments that have employed Dynamic Contrast-Enhanced Magnetic Resonance Imaging?
"Currently, 15 clinical trials are researching the application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Of those, 4 have reached Phase 3. Moreover, 40 different sites across New York are running studies on this diagnostic imaging technology."
What is the aggregate quantity of participants involved in this research project?
"Indeed, the clinical trial is actively enrolling participants as suggested by its listing on clinicaltrials.gov. This research project was initially posted January 31st 2014 and has been updated once since then, on August 16th 2022. They are looking for 70 individuals to join at one dedicated site of study."
Am I eligible to participate in this experiment?
"This medical investigation is searching for 70 volunteers aged 18 to 85 who have been diagnosed with pancreatic carcinoma. Additionally, they must satisfy the following conditions: possess a high-risk genetic syndrome (e.g., BRCA 1&2, STK11, CDNK2A, PRSS1 and MSH 2&6), GROUPS 1, 2 AND 3 participants must qualify for surgical resection based on conventional imaging findings or symptoms; all volunteers are required to undertake a negative pregnancy test if applicable; consenting to join the Oregonms; all volunteers are required to undertake a negative pregnancy test if applicable; consenting to join the Oregon Pancreatic Tumor Registry (OPTR) is mandatory; those with strong"
Is acceptance into this medical study still possible for interested participants?
"Yes, clinicaltrials.gov indicates that the trial is still recruiting applicants. It was initially posted in January 2014 and last edited in August 2022; with a goal of enlisting 70 patients from 1 site."
Share this study with friends